Newsletter from CLS, September 2023

CLS is committed to developing better therapies for use in cancer care and neurosurgery. In this edition of our newsletter, you can read more about CLS’s commercial and medical milestone that was achieved at AVANT Concierge Urology in the US, and exhibitions where our TRANBERG® system and the ClearPoint Prism™ system, powered by CLS, have been demonstrated. We are also proud to present three new members that will strengthen the CLS team.

Welcome the read the full newsetter in the attached pdf.

For more information, please contact:


Liselotte Nilsson, VP Marketing, Clinical Laserthermia Systems AB

email: lotta.nilsson@clinicallaser.com

phone: +46 (0)703 736443

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and for treatment with imILT®, the Company's interstitial laser thermotherapy with potential immunostimulatory effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se. 

For more information about CLS, please visit the Company's website: www.clinicallaser.se